专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明授权

EP2677038B1 SIMULTANEOUS DIAGNOSIS KIT FOR A DISEASE DUE TO A RESPIRATORY VIRUS 有权转让
标题翻译：由于呼吸道病毒而引起疾病的同时诊断试剂盒
公开(公告)号：EP2677038B1
公开(公告)日：2017-05-17
申请号：EP12747732.1
申请日：2012-02-20
申请人： LG Life Sciences Ltd.
发明人： YOO, Eun Joo , PARK, Young Suk , KANG, Jin Seok , HEO, Ji Eun
IPC分类号： C12Q1/68 , C12N15/11 , C12Q1/04
CPC分类号： C12Q1/701 , C12Q1/6883 , C12Q2600/158 , C12Q2600/16

2. 发明公开

EP2977048A4 COMPLEX PREPARATION INCLUDING VALSARTAN AND ROSUVASTATIN CALCIUM AND MANUFACTURING METHOD THEREFOR 审中-公开
标题翻译： KOMPLEXE ZUBEREITUNG MIT VALSARTAN UND ROSUVASTATIN-CALCIUM UND HERSTELLUNGSVERFAHRENDAFÜR
公开(公告)号：EP2977048A4
公开(公告)日：2017-04-26
申请号：EP14764870
申请日：2014-03-11
申请人： LG LIFE SCIENCES LTD
发明人： SONG JEONG UK , KIM GEUN TAE , KIM SUN IL , LEE KI KON
IPC分类号： A61K31/41 , A61K9/20 , A61K31/505 , A61P3/00 , A61P3/06
CPC分类号： A61K31/505 , A61K9/2086 , A61K9/209 , A61K31/41 , A61K2300/00

3. 发明公开

EP3037412A4 INDOLE AMIDE COMPOUND AS INHIBITOR OF NECROSIS 有权转让
标题翻译：吲哚酰胺连接作为坏死抑制剂
公开(公告)号：EP3037412A4
公开(公告)日：2017-01-18
申请号：EP14838146
申请日：2014-08-21
申请人： LG LIFE SCIENCES LTD
发明人： PARK HEUI SUL , KOO SUN YOUNG , KIM HYOUNG JIN , LEE SUNG BAE , KWAK HYO SHIN , PAEK SEUNG YUP , KIM SOON HA
IPC分类号： C07D209/30 , A61K31/404 , A61P1/16 , C07D401/12 , C07D401/14 , C07D403/06 , C07D403/12 , C07D403/14 , C07D405/12
CPC分类号： C07D417/12 , A61K31/4045 , A61K31/427 , A61K31/4439 , A61K31/454 , A61K31/5377 , A61K31/541 , A61K45/06 , C07D209/42 , C07D401/12 , C07D401/14 , C07D403/06 , C07D403/12 , C07D403/14 , C07D405/14
摘要： The present invention relates to an indole amide compound represented by formula (1), a pharmaceutically acceptable salt or isomer thereof, a composition for prevention or treatment of necrosis and necrosis-associated diseases, and a method for preparing the composition, the composition comprising the indole compound or the pharmaceutically acceptable salt or isomer thereof as an active ingredient.

4. 发明公开

EP3101120A1 METHOD FOR CONTROLLING GALACTOSYLATION OF RECOMBINANT PROTEIN THROUGH OPTIMIZATION OF CULTURE MEDIUM 审中-公开
标题翻译： VERFAHREN ZUR STEUERUNG DER GALACTOSYLIUNG VON REKOMBINANTEM PROTEIN DURCH OPTIMIERUNG DES KULTURMEDIUMS
公开(公告)号：EP3101120A1
公开(公告)日：2016-12-07
申请号：EP15743963.9
申请日：2015-01-29
申请人： LG Life Sciences Ltd.
发明人： JUNG, Jun , SONG, Won Seok , LEE, Jun Eok , KIM, Yeon Chul
IPC分类号： C12N5/02 , C12N5/071 , C07K16/18
CPC分类号： C12P21/005 , C07K16/00 , C07K2317/14 , C07K2317/41 , C12N2500/32 , C12N2500/60
摘要： Disclosed are a method for preparing a target recombinant protein with modulated galactosylation or a method for modulating the galactosylation of a target recombinant protein, including increasing the osmolality of a culture solution of animal cells which express a target recombinant protein during the animal cell culture; a method for preparing a target recombinant protein with modulated galactosylation or a method for modulating the galactosylation of a target recombinant protein, including supplementing asparagine to a culture solution of animal cells which express a target recombinant protein during the animal cell culture; a method for preparing a target recombinant protein with modulated galactosylation or a method for modulating the galactosylation of a target recombinant protein, including increasing the osmolality of an animal cell culture which expresses a target recombinant protein and supplementing asparagine thereto during the animal cell culture; and a target recombinant protein with modulated galactosylation, which is prepared by the method.
摘要翻译：公开了一种制备具有调节的半乳糖基化的靶重组蛋白的方法或调节靶重组蛋白的半乳糖基化的方法，包括增加在动物细胞培养期间表达靶重组蛋白的动物细胞培养液的重量克分子渗透压浓度; 制备具有调节的半乳糖基化的靶重组蛋白的方法或调节靶重组蛋白的半乳糖基化的方法，包括在动物细胞培养期间向表达靶重组蛋白的动物细胞的培养液中补充天冬酰胺; 用于制备具有调节的半乳糖基化的靶重组蛋白的方法或调节靶重组蛋白的半乳糖基化的方法，包括在动物细胞培养期间增加表达靶重组蛋白并在其中补充天冬酰胺的动物细胞培养物的重量克分子渗透压浓度; 和通过该方法制备的具有调节的半乳糖基化的靶重组蛋白。

5. 发明公开

EP2616047A4 NON-AQUEOUS OILY INJECTABLE FORMULATION EXHIBITING PRESERVATIVE EFFICACY 审中-公开
标题翻译： NICHTWÄSSRIGEUNDÖLIGEINJEKTIONSFORMULIERUNG MIT KONSERVIERUNGSWIRKUNG
公开(公告)号：EP2616047A4
公开(公告)日：2016-04-27
申请号：EP11825390
申请日：2011-09-09
申请人： LG LIFE SCIENCES LTD
发明人： SO JIN EON , YEO DONG JUN , JANG YOON-SEON
IPC分类号： A61K31/728 , A61K9/08
CPC分类号： A61K47/10 , A61K9/0019 , A61K9/08 , A61K31/728 , A61K47/14
摘要： Disclosed herein is preferably a multi-dose type non-aqueous oily injectable formulation including; an active ingredient (drug) expressing therapeutic effects, which is dissolved, dispersed or suspended in a therapeutically effective amount, in oil. The disclosed non-aqueous oily injectable formulation may include; an oil-affinitive preservative, and a hydrophilic excipient non-phase separable from the oil-affinitive preservative when the excipient is mixed with the oil-affinitive preservative.
摘要翻译：本文公开的是多剂型非油性可注射制剂，其包括：表达治疗效果的活性成分（药物），其以治疗有效量溶解，分散或悬浮在油中。所公开的非水性油性可注射制剂可包括：油性亲和性防腐剂，以及当赋形剂与油性亲和性防腐剂混合时，与油性亲和性防腐剂可分离的亲水性赋形剂非相。

6. 发明公开

EP2977048A1 COMPLEX PREPARATION INCLUDING VALSARTAN AND ROSUVASTATIN CALCIUM AND MANUFACTURING METHOD THEREFOR 审中-公开
标题翻译：根据上述制造缬沙坦和瑞舒伐他汀钙和工艺复合制剂
公开(公告)号：EP2977048A1
公开(公告)日：2016-01-27
申请号：EP14764870.3
申请日：2014-03-11
申请人： LG Life Sciences Ltd.
发明人： SONG, Jeong Uk , KIM, Geun Tae , KIM, Sun Il , LEE, Ki Kon
IPC分类号： A61K31/41 , A61K31/505 , A61P3/06 , A61P3/00
CPC分类号： A61K31/505 , A61K9/2086 , A61K9/209 , A61K31/41 , A61K2300/00
摘要： The present invention relates to a pharmaceutical composition including valsartan and rosuvastatin calcium as active ingredients, and a manufacturing method therefor. The pharmaceutical composition including valsartan and rosuvastatin calcium according to the present invention can alleviate side effects of the existing single preparations and simultaneously improve compliance of patients having a cardiovascular disease, a hyperlipidemic disease and a complex disease thereof, and increases treatment and prevention effects, and in particular, obtains synergistic effects in treating hyperlipidemia, and enhances the dissolution rate of valsartan and rosuvastatin calcium and treatment effects by granulating valsartan and mixing rosuvastatin calcium.

7. 发明公开

EP2917180A1 GPR40 RECEPTOR AGONIST, METHODS OF PREPARING THE SAME, AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME AS AN ACTIVE INGREDIENT 审中-公开
标题翻译： GPR40受体激动剂，方法其制造和药物组合物根据活跃
公开(公告)号：EP2917180A1
公开(公告)日：2015-09-16
申请号：EP13852767.6
申请日：2013-11-08
申请人： LG Life Sciences Ltd.
发明人： LEE, Sung Bae , PAEK, Seung Yup , YOON, Sook Kyung , YOON, Seung Hyun , CHOI, Jeung Soon
IPC分类号： C07D209/22 , C07D409/04 , A61K31/404 , A61P3/10
CPC分类号： C07D471/04 , C07D209/08 , C07D209/12 , C07D209/30 , C07D231/56 , C07D235/26 , C07D249/18 , C07D261/20 , C07D401/04 , C07D401/06 , C07D403/06 , C07D405/06 , C07D405/12 , C07D409/04 , C07D413/12 , C07D413/14 , C07D417/06
摘要： The present invention relates to a novel compound having GPR40 receptor agonist activity that promotes insulin secretion and inhibits blood sugar rise after glucose loading, and is thereby useful for the treatment of diabetes and complications thereof, the preparation method thereof and pharmaceutical composition containing them as an active ingredient.

8. 发明授权

EP2635580B1 HYDRATE OF 1-{(2S)-2-AMINO-4-[2,4-BIS(TRIFLUOROMETHYL)-5,8-DI- HYDROPYRIDO[3,4-D]PYRIMIDIN-7(6H)-YL]-4-OXOBUTYL}-5,5-DIFLUORO-PIPERIDIN-2-ONE TARTRATE 无效
标题翻译：的1水合物 - {（2S）-2-氨基-4- [2,4-双（三氟甲基）-5,8- DI-HYDROPYRIDO- [3,4-d]嘧啶-7-（6H）基] -4-氧代丁基} -5,5-二氟 - 哌啶-2--ON-酒石酸
公开(公告)号：EP2635580B1
公开(公告)日：2015-08-12
申请号：EP11838195.3
申请日：2011-10-31
申请人： LG Life Sciences Ltd
发明人： PARK, Ki Sook , YUN, Jung Min , KIM, Bong Chan , KIM, Kyu Young , LEE, Ji Hye
IPC分类号： C07D471/04 , A61K31/519 , A61P3/10 , A61P3/04
CPC分类号： C07D471/04

9. 发明公开

EP2611776A4 PRODUCTION METHOD OF INTERMEDIATE COMPOUND FOR SYNTHESIZING MEDICAMENT 有权转让
标题翻译： PROCESS用于制备药物的中间体化合物的合成
公开(公告)号：EP2611776A4
公开(公告)日：2014-08-20
申请号：EP11822081
申请日：2011-08-25
申请人： LG LIFE SCIENCES LTD
发明人： KIM BONG CHAN , KIM KYU YOUNG , LEE HEE BONG , AN JI EUN , LEE KYU WOONG
IPC分类号： C07D211/36 , A61K31/45 , A61P3/10 , C07D211/76 , C07D471/04
CPC分类号： C07D211/76

10. 发明公开

EP2635580A2 HYDRATE OF 1-{(2S)-2-AMINO-4-[2,4-BIS(TRIFLUOROMETHYL)-5,8-DI- HYDROPYRIDO[3,4-D]PYRIMIDIN-7(6H)-YL]-4-OXOBUTYL}-5,5-DIFLUORO-PIPERIDIN-2-ONE TARTRATE 无效
标题翻译：的1水合物 - {（2S）-2-氨基-4- [2,4-双（三氟甲基）-5,8- DI-HYDROPYRIDO- [3,4-d]嘧啶-7-（6H）基] -4-氧代丁基} -5,5-二氟 - 哌啶-2--ON-酒石酸
公开(公告)号：EP2635580A2
公开(公告)日：2013-09-11
申请号：EP11838195.3
申请日：2011-10-31
申请人： LG Life Sciences Ltd
发明人： PARK, Ki Sook , YUN, Jung Min , KIM, Bong Chan , KIM, Kyu Young , LEE, Ji Hye
IPC分类号： C07D471/04 , A61K31/519 , A61P3/10 , A61P3/04
CPC分类号： C07D471/04
摘要： The present invention relates to 1.5 hydrate of of 1-{(2S)-2-amino-4-[2,4-bis (trifluoromethyl)-5,8-dihydropyrido[3,4-d]pyrimidin-7(6H)-yl]-4-oxobutyl}-5,5-di-fluoropiperidin-2-one tartrate, a process for preparing the same, and a pharmaceutical composition for inhibiting DPP-IV, which comprises said compound as the active component.

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式